{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bawa Z"],"funding":["The Lambert Initiative for Cannabinoid Therapeutics"],"pagination":["e082927"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966725"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(3)"],"pubmed_abstract":["Introduction
The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of CBD. Relatively few studies have investigated the efficacy of lower (<300 mg) oral doses, typical of those available in over-the-counter CBD products.Methods
We present a protocol for a randomised, double-blind, placebo-controlled, parallel-group clinical trial investigating the effects of a low oral dose (150 mg) of CBD on acute psychosocial stress, situational anxiety, motion sickness and cybersickness in healthy individuals. Participants (n=74) will receive 150 mg of CBD or a matched placebo 90 min before completing three virtual reality "],"journal":["BMJ open"],"pubmed_title":["Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial."],"pmcid":["PMC10966725"],"funding_grant_id":["This work was supported by The Lambert Initiative"],"pubmed_authors":["McCartney D","Bedoya-Perez M","Lau NS","Bawa Z","McGregor IS","Fox R","MacDougall H"],"additional_accession":[]},"is_claimable":false,"name":"Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial.","description":"Introduction
The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of CBD. Relatively few studies have investigated the efficacy of lower (<300 mg) oral doses, typical of those available in over-the-counter CBD products.Methods
We present a protocol for a randomised, double-blind, placebo-controlled, parallel-group clinical trial investigating the effects of a low oral dose (150 mg) of CBD on acute psychosocial stress, situational anxiety, motion sickness and cybersickness in healthy individuals. Participants (n=74) will receive 150 mg of CBD or a matched placebo 90 min before completing three virtual reality ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-15T15:29:11.003Z","creation":"2024-12-03T23:55:46.933Z"},"accession":"S-EPMC10966725","cross_references":{"pubmed":["38531572"],"doi":["10.1136/bmjopen-2023-082927"]}}